Genomics Core

该项目的第一个具体目标是为Cobre调查人员和合作者提供访问国家 最先进的高通量基因分析平台，其他尖端设备，以及实验 能力。基因发现和新兴技术正在从根本上改变生物医学研究和 我们的科布雷研究人员解开自身免疫复杂基因组结构的方法 疾病。基因组学核心是Cobre研究人员访问尖端技术的中心资源 允许他们的研究项目开发和测试他们的假说的基因组技术， 因此，基因组学核心对我们中心研究人员的成功至关重要。 该项目的第二个具体目标是将基因组学核心从Cobre补贴的设施转移到 提供给一个自给自足的企业实体，由OMRF内部和外部用户提供支持。这个 基因组学核心的能力使其对那些计划研究的研究人员特别有吸引力 结合基因组学的项目。因此，研究人员已经并有望继续利用 将核心作为一个简单的服务费单位，或在资助赠款中以分包合同形式使用。带着我们的 Cobre和外部调查人员对服务的需求很高，Core准备追求多个 在我们逐步实现总体财政自给自足的过程中，通过各种机制提供资金 此外，随着外显子组和人类患者全基因组测序的拥抱，核心 可以扩大其在当地的影响，并通过提供医疗诊断测试打开全新的收入来源 除了我们支持研究的中心重点之外。预计扩展到临床 基因组学，加上来自其他机制的越来越多的赠款支持，将导致核心 5年后完全自给自足。

The first specific aim of this project is to provide COBRE Investigators and collaborators access to state of the art high throughput genetic analysis platforms, other sophisticated equipment, and experimental capabilities. Genetic discoveries and emerging technologies are radically changing biomedical research and the methods by which our COBRE investigators unravel the complex genomic architecture of autoimmune diseases. The Genomics Core serves as the central resource for COBRE investigators to access cuttingedge genomic technologies that allow their research programs to develop and test their hypotheses, therefore, the Genomics Core is highly significant and vital to the success of our Center investigators. The second specific aim of this project is to transition the Genomics Core from a COBRE-subsidized facility to a self-sustaining business entity supported by users both internal to OMRF as well as external. The capabilities of the Genomics Core make it particularly attractive to those researchers planning research projects that incorporate genomics. As such, researchers have utilized and can be expected to continue utilizing the Core as a simple fee-for-service unit or in a sub-contractual setting in funded grants. With our services in high demand from both COBRE and external investigators, the Core is poised to pursue multiple lines of funding through various mechanisms in our move towards overall financial self-sufficiency in Phase III. Furthermore, with the embrace of exome and whole genome sequencing of human patients, the Core could expand its local impact and open an entirely new revenue stream by providing medical diagnostic tests in addition to our central focus of supporting research. It is anticipated that the expansion into clinical genomics, coupled with increasing grant support from other mechanisms, will lead to the Core becoming completely self-sufficient at the end of 5 years.